# CAH earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/CAH) · [Earnings tab](https://www.lopjlb.com/stock/CAH?tab=earnings) Updated: 2026-09-07T04:50:49 Quarters analyzed: 8 ## Cross-quarter narrative Across eight quarterly calls, Cardinal Health moved from early FY25 pressure points—health‑welfare cost spikes, VA contract loss, and a moly‑99 shortage—to a narrative of broad demand strength and disciplined capital deployment. Management tone improved, repeatedly raising EPS guidance while acknowledging tariff and commodity headwinds. Gross margins rose year‑over‑year, driven by pharma specialty mix and acquisition synergies, though GMPD margins remained vulnerable to tariffs and cost inflation. The company completed several acquisitions (ION, GI Alliance, ADS, Solaris) and expanded distribution and logistics assets, while many integration projects stayed on track. Tariff exposure evolved from a risk to a recurring cost factor with uncertain refund timing. COVID‑19 vaccine distribution remained a modest drag. Capital returned to shareholders accelerated, and free cash flow grew, supporting share repurchases and debt reduction. Emerging concerns now focus on commodity price volatility, IRA pricing impacts, and goodwill impairments, indicating a shift from early operational disruptions to macro‑economic and regulatory challenges. ## Latest CallCard · Q4 Cardinal Health posted a strong FY26 Q4 with 30% earnings growth, solid cash flow and continued demand, while reaffirming FY27 EPS guidance amid modest tariff and commodity cost uncertainties. **Guidance:** maintained — FY27 EPS growth guidance of 13%‑15% is reaffirmed, with segment revenue and profit targets outlined. **Tone:** mgmt 0.8 · Q&A pressure 0.4 · divergence 0.3 Prepared remarks highlighted a strong quarter, resilient demand and momentum into FY27, reflecting an upbeat outlook. ### Demand visibility Demand remains strong across Pharma and Specialty solutions. Resilient demand environment, brand sales growth, generic conversions and specialty margin expansion underpin visibility, though outsized demand is not assumed. ### Margins / costs Margins improving with disciplined cost management. Gross profit rose 16% to $2.6B while SG&A grew 9.5%; ongoing commodity cost pressure (diesel, resins) is being monitored for margin impact. ### Capital allocation Robust cash generation supports share repurchases and capex. Adjusted free cash flow $5B, $1.35B share buybacks FY26, $700M capex planned FY27, and a new $4B revolving credit facility. ### Milestones - **Strive Medical acquisition** [delivered]: Acquisition completed and integrated. - **Consumer Health Logistics Center** [delivered]: Completed first full year of operations, elevating OTC service levels. - **Innovative Care Pharmacy (La Vergne)** [delivered]: Opened differentiated specialty pharmacy for cell and gene therapies. - **Sonexus integration into Nuclear platform** [delivered]: Created seamless digital workflow for radiopharmaceuticals. - **OptiFreight Shipment Navigator & Tracking Beacon** [new]: Tech‑forward logistics products launched last quarter. - **GMPD improvement plan** [on_track]: Continued focus on brand growth, simplification and cost optimization. - **Solar acquisition lap** [new]: Planned to lap the Solaris acquisition in Q2 FY27. - **AdaptHealth Diabetes Health tuck‑in** [new]: Announced acquisition to add 2% profit growth. ### Fears / risks - **Tariff volatility**: IEEPA tariff refunds are non‑recurring; future tariff tailwinds or headwinds could affect profitability. - **Commodity cost pressure**: Higher diesel, resin and other oil‑based commodity prices may erode margins if sustained. - **Regulatory changes**: Potential IRA price changes and 340B reforms could impact volume and margins. - **Geopolitical risk**: Prolonged Iran conflict could move GMPD profit to the lower end of its guide. - **Generic conversion reliance**: Profitability benefits depend on continued brand‑to‑generic conversions. - **Customer concentration**: Renewal of largest customer (CVS) is critical; any loss could affect revenue. - **Macro‑economic uncertainty**: Evolving macro landscape could affect demand and cost structures. - **M&A integration risk**: Integration of recent acquisitions (Strive, AdaptHealth) must deliver expected synergies. ### Key quotes > “We delivered a strong fourth quarter, concluding a fiscal '26 defined by consistent execution and broad-based performance across the enterprise.” — Jason Hollar > “Strong demand, strong execution, strong profit, strong adjusted free cash flow, strong liquidity, targeted and increased investments in the business, incremental return of capital to shareholders.” — Aaron Alt > “We are well positioned to continue delivering long-term value for our shareholders, customers and the patients that they serve.” ## Quarter one-liners - **2026 Q4:** Cardinal Health posted a strong FY26 Q4 with 30% earnings growth, solid cash flow and continued demand, while reaffirming FY27 EPS guidance amid modest tariff and commodity cost uncertainties. - **2026 Q3:** Cardinal Health posted strong Q3 FY26 results, raised full‑year EPS and free‑cash‑flow guidance, and highlighted continued demand across pharma, specialty and other growth businesses while noting tariff‑refund timing uncertainty and ongoing integration work. - **2026 Q2:** Cardinal Health posted double‑digit profit growth across all five segments, raised FY2026 EPS guidance to $10.15‑$10.35, highlighted specialty momentum, completed the Solaris Health acquisition and ADS integration progress, while noting tariff impacts and timing of brand restocking as near‑term cons - **2026 Q1:** Cardinal Health Q1 FY26: 37% operating earnings growth, raises FY26 EPS guidance to $9.65-$9.85 on broad-based segment strength and pending Solaris acquisition. - **2025 Q4:** Cardinal Health posted solid Q4 results, raised FY26 EPS guidance to $9.30‑$9.50, highlighted strong pharma and other‑segment demand, and announced the Solaris Health acquisition pending Q2 FY26 closure. - **2025 Q3:** Cardinal Health reports strong Q3 FY25 with broad-based segment profit growth, raises FY25 EPS guidance to $8.05-$8.15, and highlights tariff mitigation in GMPD while integrating acquisitions. - **2025 Q2:** Cardinal Health Q2 FY25 beat expectations, raised EPS guidance, highlighted strong pharma and specialty performance, completed GI Alliance and ION acquisitions, noted modest COVID vaccine headwind and tariff uncertainty. - **2025 Q1:** Cardinal Health Q1 FY25 saw strong pharma demand and raised EPS guidance, but faces health‑welfare cost headwinds, GMPD margin pressure and a nuclear raw‑material shortage. ## Theme arcs - **Tariff exposure** (deteriorating): Costs rising and refund timing uncertain across FY25‑FY26 - **Demand strength** (improving): Broad-based pharma, specialty and other segment demand grew with new customer wins - **Margin performance** (improving): Gross margin expansion offset by GMPD pressure - **Acquisition integration** (stable): Major deals delivered; integration progressing on schedule - **Health & Welfare cost volatility** (resolved): Spike confined to Q1 FY25 - **Commodity cost pressure** (new): Elevated diesel, resin and oil‑based inputs noted in Q4 FY26 - **Regulatory environment** (new): Regulatory uncertainty surfaced in later quarters ## Guidance path 2025 Q1:raised → 2025 Q2:raised → 2025 Q3:raised → 2025 Q4:raised → 2026 Q1:raised → 2026 Q2:raised → 2026 Q3:raised → 2026 Q4:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/CAH`